天坛生物上半年实现营收31.10亿元采浆量1361吨巩固龙头地位

Core Viewpoint - TianTan Biological disclosed its 2025 semi-annual report, showing a revenue of 3.11 billion yuan, a year-on-year increase of 9.47%, while the net profit attributable to shareholders decreased by 12.88% to 633 million yuan [1] Financial Performance - The company achieved a revenue of 3.11 billion yuan in the first half of 2025, reflecting a growth of 9.47% compared to the previous year [1] - The net profit attributable to shareholders was 633 million yuan, which represents a decline of 12.88% year-on-year [1] Operational Highlights - The number of single plasma collection stations and the scale of plasma collection continue to maintain a leading position in China, with a total of 107 stations across 16 provinces/regions, of which 85 are operational [1] - The company has made significant progress in innovative research and development, with several new products achieving milestones, including the approval of a new immunoglobulin product [1] Project and Technology Development - The company is actively promoting engineering projects and information technology construction, accelerating smart upgrades and industrial collaboration, which enhances production and management efficiency [1] - The Chengdu Rongsheng recombinant factor workshop project has completed acceptance inspection, and the production of recombinant human coagulation factor VIII is underway [1] International Business Strategy - The company is implementing its internationalization strategy, continuously advancing international market development and registration preparations, and has initiated product registration processes in multiple target markets [1] - The company has achieved progress in the registration of intravenous immunoglobulin products for international markets [1] Product Portfolio - The company operates seven blood product manufacturing enterprises, offering human albumin, human immunoglobulin, and coagulation factor products, with a total of 15 varieties and 102 production licenses [1]